The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line,

The prospects for several drug makers—and their investors—are likely to be affected as clinical trial results for key medications are reported this year. For an example of what a bad outcome can have on a company's share price, look no further than what happened to Eli Lilly and Co.'s (LLY) stock on Monday when the Indianapolis-based pharma company reported mixed results in tests of its Alzheimer's treatment. On the news, Lilly's shares took a haircut of nearly $20 to about $188.

Eli Lilly will get a chance to redeem itself when it also gets a readout this year on its

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.

Abbott

Abbott Laboratories (ABT) has a market cap of $193 billion. It has outperformed the S&P 500 by 12.01% over the past year.

As of Tuesday, the share price was 76.87% above the 52-week low and 5.36% below the 52-week high.

The company, which manufactures medical devices and adult and pediatric nutritional products, has a GuruFocus profitability rating of 7 out of 10. The return on equity of 10.9%

Danish pharmaceutical giant Novo Nordisk AS (NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.

Novo obtains the know-how with the $1.8 billion purchase of Emisphere Technologies Inc. (EMIS), a New Jersey-based company that specializes in drug delivery. Emisphere trades over the counter.

Novo recently used the Emisphere technology under license to develop its diabetes drug, Rybelsus—the first and only oral type of a class of drugs called glucagon-like peptide agonists, according to an article in FiercePharma. GL-1 drugs not only improve blood sugar control, but may

In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (BIIB), Novo Nordisk A/S (NVO), ResMed Inc. (RMD) and Illumina Inc. (ILMN) according to the All-in-One Screener, a Premium feature of GuruFocus.

U.S. markets slip as coronavirus cases increase around the globe

On Monday, the Dow Jones Industrial Average closed at 28,195.42, down 410.89 points from last Friday's close of 28,606.31 as surging coronavirus cases around the globe dampened investor sentiment.

According to Johns Hopkins University statistics, global cases of Covid-19

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are AmerisourceBergen Corp. (ABC), Chemed Corp. (CHE), Neogen Corp. (NEOG), Novo Nordisk A/S (NVO) and ResMed Inc. (RMD) according to the All-in-One Screener, a Premium feature of GuruFocus.

U.S. markets slip on renewed fears of coronavirus spread

On Tuesday, the Dow Jones Industrial Average closed at 27,451.81, down 132.25 points from Monday's close of 27,584.06. The 30-stock index traded at an intraday low of 27,338 earlier in

According to the GuruFocus All-in-One Screener, a Premium feature, the stocks of the following guru-owned health care companies have outperformed the S&P 500 Index over the past 12 months through July 10.

UnitedHealth

UnitedHealth Group Inc. (UNH) has a market cap of $287.94 billion. It has outperformed the S&P 500 by 7.42% over the past year.

Shares are trading with a price-earnings ratio of 7.08. As of Friday, the share price was 61.74% above the 52-week low and 3.87% below the 52-week high.

The company has a GuruFocus profitability rating of 8 out of 10. The return on

Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according to a report from the Westhealth Policy Center. At the other end of the spectrum were Abbott Laboratories (ABT) and Easai Co. (TSE:4523).

In simplest terms, ROIC is a profitability ratio that indicates just how efficient a company is turning capital into profit. It measures the return that an investment generates for those who have provided capital (i.e., bondholders and stockholders).

ROIC can be important to investors because it is a key

Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc. (BMRN) has the most to gain. If the company’s Roctavian gets greenlighted by the Food and Drug Administration, it will become the first gene therapy for one of the world’s highest-profile inherited diseases, hemophilia A.

Hemophilia is a rare hereditary bleeding disorder that occurs in a relatively small number of patients around the world. Its cause is a missing or deficient protein needed for blood clotting. Hemophilia A occurs in one in 5,000 live male births. It is about four times as common

In light of Novavax Inc. (NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (ALXN), Novo Nordisk A/S (NVO), Galapagos NV (GLPG), Regeneron Pharmaceuticals Inc. (REGN) and Vertex Pharmaceuticals Inc. (VRTX).

Novavax continues big surge on coronavirus vaccine federal aid

Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of

Growing earnings can often push share prices up. The S&P 500 Index, which is a benchmark for the U.S. market, has grown its annual earnings per share (not adjusted for inflation) by about 6.5% every year over the past five years. On the tailwind of this, the share price of the index increased by nearly 49% over the past five years, closing at a price of $3,003.37 on March 3, 2020.

Past performance is not a guarantee of future results, but it does indicate that a company has a better foundation on which to grow.

As a result of strong

"When you have to make a choice and don’t make it, that is in itself a choice."

- William James

One evening a Cherokee elder told his grandson about a battle that goes on inside people. He said, “My son, the battle is between two “wolves” inside us all. One is Evil. It is anger, envy, jealousy, sorrow, regret, greed, arrogance, self-pity, guilt, resentment, inferiority, lies, false pride, superiority, and ego. The other is Good. It is joy, peace, love, hope, serenity, humility, kindness, benevolence, empathy, generosity, truth, compassion, and faith.” The grandson thought about